Rhabdomyosarcoma Clinical Trials

20 studies are recruiting for rhabdomyosarcoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

   The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

   Stage

   Phase 1

   Ages

   2 to 18

   Site

   UCSF Benioff Children's Hospital, San Francisco, California

   Locations

   6 in total

   Run by

   ITM Solucin GmbH

   See if you can join NCT06441331 on ClinicalTrials.gov

2. FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

   Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface. Researchers want to try a new kind of treatment for RMS: They will collect a person s own T cells, a type of imm…

   Stage

   Phase 1

   Ages

   3 to 39

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06865664 on ClinicalTrials.gov

3. Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

   The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authori…

   Stage

   Phase 1

   Ages

   Up to 30

   Site

   University of Alabama/Children's of Alabama, Birmingham, Alabama

   Locations

   23 in total

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06541262 on ClinicalTrials.gov

4. A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

   This phase III trial compares higher dose chemotherapy, with vincristine, dactinomycin and cyclophosphamide, over a shorter amount of time to lower dose chemotherapy plus maintenance, with vincristine, dactinomycin, cyclophosphamide, irinotecan and vinorelbine, over a longer amount of time, along w…

   Stage

   Phase 3

   Ages

   Up to 50

   Site

   Children's Hospital of Alabama, Birmingham, Alabama

   Locations

   87 in total

   Run by

   Children's Oncology Group

   See if you can join NCT07466316 on ClinicalTrials.gov

5. Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

   Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as neede…

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT07514819 on ClinicalTrials.gov

6. Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

   This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcom…

   Stage

   Phase 1

   Ages

   1 to 23

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Children's National Research Institute

   See if you can join NCT07172958 on ClinicalTrials.gov

7. Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

   Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment. The body has different ways of fighting infect…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Texas Children's Hospital, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT04715191 on ClinicalTrials.gov

8. Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

   This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07628634 on ClinicalTrials.gov

9. Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

   This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.

   Stage

   Not phased

   Ages

   Up to 39

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   3 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06796543 on ClinicalTrials.gov

10. Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

    Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing …

    Stage

    Phase 1

    Ages

    0 to 25

    Site

    University of Florida, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT06625190 on ClinicalTrials.gov

11. Familial Investigations of Childhood Cancer Predisposition

    NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

    Stage

    Not phased

    Ages

    Any age

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT03050268 on ClinicalTrials.gov

12. Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

    This is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating with VAC in high-risk patients and the chemotherapy combinations when g…

    Stage

    Phase 2

    Ages

    Up to 22

    Site

    Stanford University, Palo Alto, California

    Locations

    3 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06023641 on ClinicalTrials.gov

13. VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

    This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

    Stage

    Phase 1

    Ages

    0 to 30

    Site

    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    7 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04796012 on ClinicalTrials.gov

14. B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

    3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate…

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT04897321 on ClinicalTrials.gov

15. Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

    Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this stu…

    Stage

    Phase 1

    Ages

    1 to 30

    Site

    New York Medical College, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT04308330 on ClinicalTrials.gov

16. Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

    This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing Sarcoma (EWS) and Desmoplastic Small Round Cell Tumor (DSRCT), as well as …

    Stage

    Phase 1

    Ages

    12 to 49

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    David S Shulman, MD

    See if you can join NCT06709495 on ClinicalTrials.gov

17. Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

    This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived fr…

    Stage

    Phase 1

    Ages

    1 to 26

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT07148050 on ClinicalTrials.gov

18. HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

    The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this therapy might help patients with sarcoma. Another goal of this study is…

    Stage

    Phase 1

    Ages

    1 to 25

    Site

    Texas Children's Hospital, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT04995003 on ClinicalTrials.gov

19. Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

    The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly c…

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    Houston Methodist Hospital, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT06198296 on ClinicalTrials.gov

20. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

    This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

    Stage

    Phase 1

    Ages

    0 to 21

    Site

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT02508038 on ClinicalTrials.gov